Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Cortes

Showing results (131-140 of 231) with videos related to

Pageof 24
Sort By:
Oncology|November 29, 2002
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancerJavier Cortes, Javier Rodriguez, Jose Manuel Aramendia, et al.
Breast Cancer Research : BCR|February 11, 2017
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR<sup>+</sup>, HER2<sup>-</sup> breast cancer that had progressed during or after prior endocrine therapyAntonino Musolino, Mario Campone, Patrick Neven, et al.
American Journal of Clinical Oncology|June 1, 2004
Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancerJavier Cortes, Javier Rodriguez, Emiliano Calvo, et al.
BMC Infectious Diseases|June 28, 2012
Predictors of human papillomavirus infection in women undergoing routine cervical cancer screening in Spain: the CLEOPATRE studyEsther Roura, Thomas Iftner, José Antonio Vidart, et al.
JAMA Oncology|October 6, 2022
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and MisinterpretationsFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Cancers|October 27, 2022
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled AnalysisSandra M Swain, Harrison Macharia, Javier Cortes, et al.
Breast (Edinburgh, Scotland)|May 27, 2025
Advancing breast cancer therapy in the era of molecular diagnosticsMaria Grazia Carnevale, Riccardo Ray Colciago, Maria Carmen De Santis, et al.
Trials|December 18, 2015
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trialDenise A Yardley, Adam Brufsky, Robert E Coleman, et al.
British Journal of Cancer|June 24, 2020
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathyKamal S Saini, Carlo Lanza, Marco Romano, et al.
Trials|February 5, 2016
Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trialDenise A Yardley, Adam Brufsky, Robert E Coleman, et al.
Pageof 24

Showing results (131-140 of 231) with videos related to

Sort By:
Pageof 24
Oncology|November 29, 2002
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancerJavier Cortes, Javier Rodriguez, Jose Manuel Aramendia, et al.
Breast Cancer Research : BCR|February 11, 2017
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR<sup>+</sup>, HER2<sup>-</sup> breast cancer that had progressed during or after prior endocrine therapyAntonino Musolino, Mario Campone, Patrick Neven, et al.
American Journal of Clinical Oncology|June 1, 2004
Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancerJavier Cortes, Javier Rodriguez, Emiliano Calvo, et al.
BMC Infectious Diseases|June 28, 2012
Predictors of human papillomavirus infection in women undergoing routine cervical cancer screening in Spain: the CLEOPATRE studyEsther Roura, Thomas Iftner, José Antonio Vidart, et al.
JAMA Oncology|October 6, 2022
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and MisinterpretationsFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Cancers|October 27, 2022
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled AnalysisSandra M Swain, Harrison Macharia, Javier Cortes, et al.
Breast (Edinburgh, Scotland)|May 27, 2025
Advancing breast cancer therapy in the era of molecular diagnosticsMaria Grazia Carnevale, Riccardo Ray Colciago, Maria Carmen De Santis, et al.
Trials|December 18, 2015
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trialDenise A Yardley, Adam Brufsky, Robert E Coleman, et al.
British Journal of Cancer|June 24, 2020
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathyKamal S Saini, Carlo Lanza, Marco Romano, et al.
Trials|February 5, 2016
Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trialDenise A Yardley, Adam Brufsky, Robert E Coleman, et al.
Pageof 24